Teprasiran

DB15064Investigational

Teprasiran is under investigation in clinical trial NCT03510897 (QPI-1002 Phase 3 for Prevention of Major Adverse Kidney Events (MAKE) in Subjects at High Risk for AKI Following Cardiac Surgery).

Mechanism: Pharmacologically active on Cellular tumor antigen p53
Curator reviewed
Code names: QPI-1002

Resolves to

Compound

UNIIO03W5S19PJCAS1231737-88-4

Targets

P04637TP53

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Teprasiran, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account